Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.

[1]  Jack Cuzick,et al.  The APTIMA HPV assay versus the hybrid capture 2 test in triage of women with ASC‐US or LSIL cervical cytology: A meta‐analysis of the diagnostic accuracy , 2013, International journal of cancer.

[2]  Jack Cuzick,et al.  New technologies and procedures for cervical cancer screening. , 2012, Vaccine.

[3]  M. Poljak,et al.  Nucleic acid tests for the detection of alpha human papillomaviruses. , 2012, Vaccine.

[4]  Marc Arbyn,et al.  p16INK4a immunocytochemistry versus human papillomavirus testing for triage of women with minor cytologic abnormalities , 2012, Cancer cytopathology.

[5]  M. Schiffman,et al.  American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer , 2012, CA: a cancer journal for clinicians.

[6]  X. Yi,et al.  Improved sensitivity of vaginal self‐collection and high‐risk human papillomavirus testing , 2012, International journal of cancer.

[7]  J. Berkhof,et al.  Evaluation of 14 triage strategies for HPV DNA‐positive women in population‐based cervical screening , 2012, International journal of cancer.

[8]  J. Cuzick,et al.  Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. , 2012, The Lancet. Oncology.

[9]  Thomas C Wright,et al.  Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study. , 2011, The Lancet. Oncology.

[10]  J. Berkhof,et al.  Clinical Validation of the cobas 4800 HPV Test for Cervical Screening Purposes , 2011, Journal of Clinical Microbiology.

[11]  M. Hudgens,et al.  Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid‐based cytology in primary cervical cancer screening: The FASE study , 2011, International journal of cancer.

[12]  Mark Schiffman,et al.  Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. , 2011, The Lancet. Oncology.

[13]  E. Lynge,et al.  Human papillomavirus testing in primary cervical screening and the cut-off level for hybrid capture 2 tests: systematic review , 2011, BMJ : British Medical Journal.

[14]  J. Berkhof,et al.  Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. , 2011, The Lancet. Oncology.

[15]  Y. Liu,et al.  A population-based clinical trial comparing endocervical high-risk HPV testing using hybrid capture 2 and Cervista from the SHENCCAST II Study. , 2011, American journal of clinical pathology.

[16]  M. Poljak,et al.  Comparison of Clinical and Analytical Performance of the Abbott RealTime High Risk HPV Test to the Performance of Hybrid Capture 2 in Population-Based Cervical Cancer Screening , 2011, Journal of Clinical Microbiology.

[17]  C. Sani,et al.  Comparison of Clinical Performance of Abbott RealTime High Risk HPV Test with That of Hybrid Capture 2 Assay in a Screening Setting , 2011, Journal of Clinical Microbiology.

[18]  J. Berkhof,et al.  Comparison of Hybrid capture 2 testing at different thresholds with cytology as primary cervical screening test , 2010, British Journal of Cancer.

[19]  Y. Liu,et al.  Human Papillomavirus Messenger RNA Assay for Cervical Cancer Screening: The Shenzhen Cervical Cancer Screening Trial I , 2010, International Journal of Gynecologic Cancer.

[20]  J. Cuzick,et al.  Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. , 2010, The Lancet. Oncology.

[21]  N. Segnan,et al.  European Guidelines for Quality Assurance in Cervical Cancer Screening. Second Edition—Summary Document , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  J. Berkhof,et al.  Comparison of the Clinical Performance of PapilloCheck Human Papillomavirus Detection with That of the GP5+/6+-PCR-Enzyme Immunoassay in Population-Based Cervical Screening , 2009, Journal of Clinical Microbiology.

[23]  A. Anttila,et al.  Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. , 2009, Journal of the National Cancer Institute.

[24]  G. Ronco,et al.  Trials comparing cytology with human papillomavirus screening. , 2009, The Lancet. Oncology.

[25]  S. Wacholder,et al.  Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study , 2009, BMJ : British Medical Journal.

[26]  K. Lakshmaiah,et al.  HPV screening for cervical cancer in rural India. , 2009, The New England journal of medicine.

[27]  Henry C Kitchener,et al.  HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. , 2009, The Lancet. Oncology.

[28]  D. Solomon,et al.  Statement on HPV DNA test utilization. , 2009, American journal of clinical pathology.

[29]  J. Cuzick,et al.  Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older , 2009, International journal of cancer.

[30]  J. Dillner,et al.  Triage of women with equivocal or low-grade cervical cytology results: a meta-analysis of the HPV test positivity rate , 2009, Journal of cellular and molecular medicine.

[31]  J. Dillner,et al.  Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening. , 2009, Journal of the National Cancer Institute.

[32]  M Arbyn,et al.  European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1 , 2008, Cytopathology : official journal of the British Society for Clinical Cytology.

[33]  Joakim Dillner,et al.  Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study , 2008, BMJ : British Medical Journal.

[34]  Feng Chen,et al.  A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. , 2008, The Lancet. Oncology.

[35]  Joakim Dillner,et al.  Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. , 2008, Vaccine.

[36]  J. Cuzick,et al.  Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. , 2008, Journal of the National Cancer Institute.

[37]  J. Berkhof,et al.  Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial , 2007, The Lancet.

[38]  J. Dillner,et al.  Human Papillomavirus and Papanicolaou Tests to Screen for Cervical Cancer , 2008 .

[39]  Stephen D Walter,et al.  Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. , 2007, The New England journal of medicine.

[40]  Diane Solomon,et al.  2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. , 2007, American journal of obstetrics and gynecology.

[41]  W. Prendiville,et al.  Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and meta-analysis of non-randomized studies. , 2007, Gynecologic oncology.

[42]  J. Dillner,et al.  Chapter 9: Clinical applications of HPV testing: a summary of meta-analyses. , 2006, Vaccine.

[43]  J. Cuzick,et al.  Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. , 2006, Journal of the National Cancer Institute.

[44]  P. Sasieni,et al.  Long‐term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia , 2006, International journal of cancer.

[45]  H. Kitchener,et al.  A report on the current status of European research on the use of human papillomavirus testing for primary cervical cancer screening , 2006, International journal of cancer.

[46]  J. Stockman.  Regression of Low-Grade Squamous Intra-epithelial Lesions in Young Women , 2006 .

[47]  D. Parkin,et al.  A cluster randomized controlled trial of visual, cytology and human papillomavirus screening for cancer of the cervix in rural India , 2005, International journal of cancer.

[48]  P. Snijders,et al.  Triage using HPV‐testing in persistent borderline and mildly dyskaryotic smears: Proposal for new guidelines , 2005, International journal of cancer.

[49]  David R. Scott,et al.  The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. , 2005, Journal of the National Cancer Institute.

[50]  S. Wacholder,et al.  A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. , 2005, The Journal of infectious diseases.

[51]  A. Moscicki,et al.  Regression of low-grade squamous intra-epithelial lesions in young women , 2004, The Lancet.

[52]  S. Syrjänen,et al.  Human Papillomavirus Testing with the Hybrid Capture 2 Assay and PCR as Screening Tools , 2004, Journal of Clinical Microbiology.

[53]  Joakim Dillner,et al.  Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. , 2004, Journal of the National Cancer Institute.

[54]  David R. Scott,et al.  Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. , 2003, Journal of the National Cancer Institute.

[55]  C J L M Meijer,et al.  The causal relation between human papillomavirus and cervical cancer. , 2002, Journal of clinical pathology.

[56]  A. Lopes,et al.  Follow up after LLETZ: could schedules be modified according to risk of recurrence? , 2001, BJOG : an international journal of obstetrics and gynaecology.